Oncologist: The efficacy and safety of cimiprizumab+radiotherapy+cyclophosphamide+GM-CSF in the treatment of recurrent/metastatic head and neck squamous cell carcinoma

Center point:

Center point:

Cimiprizumab combined with radiotherapy, cyclophosphamide and granulocyte macrophage colony stimulating factor (GM-CSF) is not as effective as other PD-1 inhibitors in patients with refractory/metastatic head and neck squamous cell carcinoma Monotherapy.

Cimiprizumab combined with radiotherapy, cyclophosphamide and granulocyte macrophage colony stimulating factor (GM-CSF) is not as effective as other PD-1 inhibitors in patients with refractory/metastatic head and neck squamous cell carcinoma Monotherapy.

The safety of cimiprizumab combination therapy is consistent with the previously reported safety of cimiprizumab single-agent therapy.

An extended cohort of a phase I study recruited R/M HNSCC patients who did not respond to at least first-line treatment, and was designed to evaluate cimiprizumab in combination with radiotherapy, cyclophosphamide, and granulocyte macrophage colony stimulating factor (GM -CSF) for the efficacy and safety of such patients.

Adverse reactions

Adverse reactions

A total of 15 patients were recruited.

The patient discontinued treatment due to disease progression The patient discontinued treatment due to disease progression

Efficacy analysis

Efficacy analysis

According to the assessment of the investigators, 1 patient achieved partial remission (6.

One patient achieved partial remission (6.

This regimen is well tolerated to R/M HNSCC, but its efficacy is weaker than that of anti-PD-1 inhibitor monotherapy.

Original source:

Babiker Hani M, Brana Irene, Mahadevan Daruka et al.

org/10.
1002/onco.
13810" target="_blank" rel="noopener">Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

in this message